Pages that link to "Q38339722"

The following pages link to Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address. (Q38339722):

Displaying 12 items.

• Approach to Patients with Severe Asthma: a Consensus Statement from the Respiratory Care Experts' Input Forum (RC-EIF), Iran (Q26777154) (← links)
• Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. (Q36113704) (← links)
• CD11b and Sca-1 Cells Exert the Main Beneficial Effects of Systemically Administered Bone Marrow-Derived Mononuclear Cells in a Murine Model of Mixed Th2/Th17 Allergic Airway Inflammation (Q36703006) (← links)
• Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. (Q39650450) (← links)
• dNP2-ctCTLA-4 inhibits German cockroach extract-induced allergic airway inflammation and hyper-responsiveness via inhibition of Th2 responses (Q41583211) (← links)
• Current and emerging treatments for severe asthma (Q42085515) (← links)
• SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. (Q42365050) (← links)
• Biologic agents for severe asthma patients: clinical perspectives and implications. (Q47576873) (← links)
• Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. (Q52657068) (← links)
• The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials (Q59791503) (← links)
• New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic (Q92696109) (← links)
• Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice (Q92701376) (← links)